{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T18:10:59Z","timestamp":1789668659579,"version":"4.0.1"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T00:00:00Z","timestamp":1783382400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T00:00:00Z","timestamp":1783382400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2026,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Neoadjuvant therapy is a cornerstone of treatment for resectable gastroesophageal junction (GEJ) tumors. Despite substantial advancements, optimal regimen selection remains challenging owing to heterogeneity in clinical trial inclusion criteria and treatment algorithms. This review synthesizes findings from pivotal randomized trials to guide evidence-based selection of neoadjuvant treatment for GEJ adenocarcinoma. In 2006, the MAGIC trial established a survival benefit with perioperative chemotherapy with epirubicin, cisplatin, and fluorouracil (ECF) compared with surgery alone. Subsequently, in 2012, CROSS demonstrated improved overall survival (OS) and R0 resection rates with neoadjuvant chemoradiotherapy (CRT) using carboplatin and paclitaxel compared with surgery alone. CRT increased pathologic complete response (pCR) rates and decreased local recurrence rates, though it had limited impact on distant recurrence rates. In 2018, the FLOT4 trial demonstrated that perioperative FLOT (fluorouracil, leucovorin, oxaliplatin, docetaxel) improved overall survival and pCR rates compared with ECF, making FLOT the new standard for perioperative chemotherapy. Several trials have since compared perioperative chemotherapy with neoadjuvant CRT. Neo-AEGIS found no survival difference; however, the predominance of ECF rather than FLOT in the chemotherapy arm limits its pertinence in the modern era. TOPGEAR demonstrated improved pCR with the addition of preoperative radiotherapy to FLOT, but no survival advantage. More recently, ESOPEC established FLOT\u2019s superiority over CROSS for OS, and MATTERHORN demonstrated improved event-free survival with the addition of immunotherapy to perioperative FLOT. FLOT is the current standard for neoadjuvant treatment in GEJ adenocarcinoma due to its superior survival outcomes. Integration of immunotherapy represents a promising avenue to further improve outcomes.<\/jats:p>","DOI":"10.1245\/s10434-026-20114-4","type":"journal-article","created":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T17:51:49Z","timestamp":1783446709000},"page":"9237-9248","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The Landmark Series: Neoadjuvant Therapy for Patients with Resectable Gastroesophageal Junction Adenocarcinomas"],"prefix":"10.1245","volume":"33","author":[{"given":"Morgan F.","family":"Pettigrew","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie G.","family":"Coburn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanghee","family":"Woo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew R.","family":"Porembka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,7]]},"reference":[{"key":"20114_CR1","unstructured":"NCCN clinical practice guidelines in oncology: esophageal and esophagogastric junction cancers. Updated July 30, 2024. Accessed 17 Nov 2024. https:\/\/Www.Nccn.Org\/Professionals\/Physician_Gls\/Pdf\/Esophageal.Pdf."},{"issue":"1","key":"20114_CR2","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/Nejmoa055531","volume":"355","author":"D Cunningham","year":"2006","unstructured":"Cunningham D, Allum WH, Stenning SP, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. New England J Med. 2006;355(1):11\u201320. https:\/\/doi.org\/10.1056\/Nejmoa055531.","journal-title":"New England J Med"},{"issue":"22","key":"20114_CR3","doi-asserted-by":"publisher","first-page":"2074","DOI":"10.1056\/Nejmoa1112088","volume":"366","author":"P Van Hagen","year":"2012","unstructured":"Van Hagen P, Hulshof MCCM, Van Lanschot JJB, et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. New England J Med. 2012;366(22):2074\u201384. https:\/\/doi.org\/10.1056\/Nejmoa1112088.","journal-title":"New England J Med"},{"issue":"10184","key":"20114_CR4","doi-asserted-by":"publisher","first-page":"1948","DOI":"10.1016\/S0140-6736(18)32557-1","volume":"393","author":"S-E Al-Batran","year":"2019","unstructured":"Al-Batran S-E, Homann N, Pauligk C, et al. Perioperative chemotherapy with fluorouracil plus Leucovorin, Oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and Epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2\/3 trial. Lancet. 2019;393(10184):1948\u201357. https:\/\/doi.org\/10.1016\/S0140-6736(18)32557-1.","journal-title":"Lancet."},{"issue":"11","key":"20114_CR5","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1016\/S2468-1253(23)00243-1","volume":"8","author":"JV Reynolds","year":"2023","unstructured":"Reynolds JV, Preston SR, O\u2019Neill B, et al. Trimodality therapy versus perioperative chemotherapy in the management of locally advanced adenocarcinoma of the oesophagus and oesophagogastric junction (Neo-AEGIS): an open-label, randomised, phase 3 trial. Lancet Gastroenterol Hepatol. 2023;8(11):1015\u201327. https:\/\/doi.org\/10.1016\/S2468-1253(23)00243-1.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"19","key":"20114_CR6","doi-asserted-by":"publisher","first-page":"1810","DOI":"10.1056\/Nejmoa2405195","volume":"391","author":"T Leong","year":"2024","unstructured":"Leong T, Smithers BM, Michael M, et al. Preoperative chemoradiotherapy for resectable gastric cancer. New England J Med. 2024;391(19):1810\u201321. https:\/\/doi.org\/10.1056\/Nejmoa2405195.","journal-title":"New England J Med"},{"issue":"4","key":"20114_CR7","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1056\/Nejmoa2409408","volume":"392","author":"J Hoeppner","year":"2025","unstructured":"Hoeppner J, Brunner T, Schmoor C, et al. Perioperative chemotherapy or preoperative chemoradiotherapy in esophageal cancer. N Engl J Med. 2025;392(4):323\u201335. https:\/\/doi.org\/10.1056\/Nejmoa2409408.","journal-title":"N Engl J Med."},{"issue":"3","key":"20114_CR8","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1056\/Nejmoa2503701","volume":"393","author":"YY Janjigian","year":"2025","unstructured":"Janjigian YY, Al-Batran SE, Wainberg ZA, et al. Perioperative durvalumab in gastric and gastroesophageal junction cancer. New England J Med. 2025;393(3):217\u201330. https:\/\/doi.org\/10.1056\/Nejmoa2503701.","journal-title":"New England J Med"},{"issue":"1","key":"20114_CR9","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1001\/Jamaoncol.2017.2805","volume":"4","author":"AA Mokdad","year":"2018","unstructured":"Mokdad AA, Yopp AC, Polanco PM, Mansour JC, Reznik SI, Heitjan DF, Porembka MR. Adjuvant chemotherapy vs. postoperative observation following preoperative chemoradiotherapy and resection in gastroesophageal cancer: a propensity score\u2013matched analysis. JAMA Oncol. 2018;4(1):31\u20138. https:\/\/doi.org\/10.1001\/Jamaoncol.2017.2805.","journal-title":"JAMA Oncol"},{"issue":"5","key":"20114_CR10","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1016\/S1470-2045(18)30132-3","volume":"19","author":"A Cats","year":"2018","unstructured":"Cats A, Jansen EP, van Grieken NC, et al. Chemotherapy versus chemoradiotherapy after surgery and preoperative chemotherapy for resectable gastric cancer (critics): an international, open-label, randomised phase 3 trial. Lancet Oncol. 2018;19(5):616\u201328. https:\/\/doi.org\/10.1016\/S1470-2045(18)30132-3.","journal-title":"Lancet Oncol"},{"key":"20114_CR11","doi-asserted-by":"publisher","unstructured":"Hoeppner J, Brunner T, Lordick F, et al. Prospective randomized multicenter phase III trial comparing perioperative chemotherapy (FLOT protocol) to neoadjuvant chemoradiation (CROSS protocol) in patients with adenocarcinoma of the esophagus (ESOPEC trial). J Clin Oncol. 2024;42(17_Suppl):Lba1\u2013Lba1. https:\/\/doi.org\/10.1200\/Jco.2024.42.17_Suppl.Lba1","DOI":"10.1200\/Jco.2024.42.17_Suppl.Lba1"},{"key":"20114_CR12","unstructured":"Nyberg K. Perioperative chemotherapy outperforms neoadjuvant chemoradiotherapy as curative treatment of esophageal\/Gej adenocarcinoma in the Esopec trial. Asco daily news. Accessed 22 Nov 2024. Https:\/\/Dailynews.Ascopubs.Org\/Do\/Perioperative-Chemotherapy-Outperforms-Neoadjuvant-Chemoradiotherapy-Curative-Treatment."},{"key":"20114_CR13","doi-asserted-by":"publisher","first-page":"S1315","DOI":"10.1016\/J.Annonc.2023.10.074","volume":"34","author":"YY Janjigian","year":"2023","unstructured":"Janjigian YY, Al-Batran SE, Wainberg ZA, et al. Lba73 pathological complete response (pCR) To Durvalumab Plus 5-Fluorouracil, Leucovorin, Oxaliplatin and Docetaxel (FLOT) In Resectable Gastric and Gastroesophageal Junction Cancer (GC\/GEJC): Interim Results Of The Global, Phase III Matterhorn Study. Annals Oncol. 2023;34:S1315\u20136. https:\/\/doi.org\/10.1016\/J.Annonc.2023.10.074.","journal-title":"Annals Oncol."},{"issue":"18","key":"20114_CR14","doi-asserted-by":"publisher","first-page":"4583","DOI":"10.1158\/1078-0432.Ccr-10-0733","volume":"16","author":"KN Kodumudi","year":"2010","unstructured":"Kodumudi KN, Woan K, Gilvary DL, Sahakian E, Wei S, Djeu JY. A novel chemoimmunomodulating property of docetaxel: suppression of myeloid-derived suppressor cells in tumor bearers. Clin Cancer Res. 2010;16(18):4583\u201394. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-10-0733.","journal-title":"Clin Cancer Res."},{"issue":"8","key":"20114_CR15","doi-asserted-by":"publisher","first-page":"3052","DOI":"10.1158\/0008-5472.Can-09-3690","volume":"70","author":"J Vincent","year":"2010","unstructured":"Vincent J, Mignot G, Chalmin F, et al. 5-fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity. Cancer Res. 2010;70(8):3052\u201361. https:\/\/doi.org\/10.1158\/0008-5472.Can-09-3690.","journal-title":"Cancer Res."},{"issue":"10294","key":"20114_CR16","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S0140-6736(21)00797-2","volume":"398","author":"YY Janjigian","year":"2021","unstructured":"Janjigian YY, Shitara K, Moehler M, et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (checkmate 649): a randomised, open-label, phase 3 trial. Lancet. 2021;398(10294):27\u201340. https:\/\/doi.org\/10.1016\/S0140-6736(21)00797-2.","journal-title":"Lancet"},{"issue":"4","key":"20114_CR17","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1007\/S10120-018-00909-5","volume":"22","author":"YJ Bang","year":"2019","unstructured":"Bang YJ, Kang YK, Catenacci DV, et al. Pembrolizumab alone or in combination with chemotherapy as first-line therapy for patients with advanced gastric or gastroesophageal junction adenocarcinoma: results from the phase Ii nonrandomized keynote-059 study. Gastric Cancer. 2019;22(4):828\u201337. https:\/\/doi.org\/10.1007\/S10120-018-00909-5.","journal-title":"Gastric Cancer"},{"issue":"10","key":"20114_CR18","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1001\/Jamaoncol.2020.3370","volume":"6","author":"K Shitara","year":"2020","unstructured":"Shitara K, Van Cutsem E, Bang YJ, et al. Efficacy and safety of pembrolizumab or pembrolizumab plus chemotherapy vs. chemotherapy alone for patients with first-line, advanced gastric cancer: the keynote-062 phase 3 randomized clinical trial. JAMA Oncol. 2020;6(10):1571\u201380. https:\/\/doi.org\/10.1001\/Jamaoncol.2020.3370.","journal-title":"JAMA Oncol."},{"issue":"12","key":"20114_CR19","doi-asserted-by":"publisher","first-page":"E2139573","DOI":"10.1001\/Jamanetworkopen.2021.39573","volume":"4","author":"T Filleron","year":"2021","unstructured":"Filleron T, Bachelier M, Mazieres J, et al. Assessment of treatment effects and long-term benefits in immune checkpoint inhibitor trials using the flexible parametric cure model: a systematic review. Jama Netw Open. 2021;4(12):E2139573\u2013E2139573. https:\/\/doi.org\/10.1001\/Jamanetworkopen.2021.39573.","journal-title":"Jama Netw Open."},{"issue":"8","key":"20114_CR20","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1016\/S2468-1253(24)00156-0","volume":"9","author":"Y-K Kang","year":"2024","unstructured":"Kang Y-K, Terashima M, Kim Y-W, et al. Adjuvant nivolumab plus chemotherapy versus placebo plus chemotherapy for stage Iii gastric or gastro-oesophageal junction cancer after gastrectomy with D2 or more extensive lymph-node dissection (attraction-5): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial. Lancet Gastroenterol Hepatol. 2024;9(8):705\u201317. https:\/\/doi.org\/10.1016\/S2468-1253(24)00156-0.","journal-title":"Lancet Gastroenterol Hepatol."},{"issue":"2","key":"20114_CR21","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/S1470-2045(23)00541-7","volume":"25","author":"K Shitara","year":"2024","unstructured":"Shitara K, Rha SY, Wyrwicz LS, et al. Neoadjuvant and adjuvant pembrolizumab plus chemotherapy in locally advanced gastric or gastro-oesophageal cancer (keynote-585): an interim analysis of the multicentre, double-blind, randomised phase 3 study. Lancet Oncol. 2024;25(2):212\u201324. https:\/\/doi.org\/10.1016\/S1470-2045(23)00541-7.","journal-title":"Lancet Oncol"},{"issue":"26","key":"20114_CR22","doi-asserted-by":"publisher","first-page":"4043","DOI":"10.1200\/Jco.2007.11.5287","volume":"25","author":"DS Shewach","year":"2007","unstructured":"Shewach DS, Lawrence TS. Antimetabolite Radiosensitizers. J Clin Oncol. 2007;25(26):4043\u201350. https:\/\/doi.org\/10.1200\/Jco.2007.11.5287.","journal-title":"J Clin Oncol"},{"issue":"13","key":"20114_CR23","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1056\/Nejmoa2032125","volume":"384","author":"RJ Kelly","year":"2021","unstructured":"Kelly RJ, Ajani JA, Kuzdzal J, et al. Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer. New England J Med. 2021;384(13):1191\u2013203. https:\/\/doi.org\/10.1056\/Nejmoa2032125.","journal-title":"New England J Med"},{"key":"20114_CR24","doi-asserted-by":"publisher","first-page":"1431957","DOI":"10.3389\/Fimmu.2024.1431957","volume":"15","author":"PF Zhang","year":"2024","unstructured":"Zhang PF, Chen Y, Li WK, et al. Sox combined with tislelizumab and low-dose radiation therapy for the neoadjuvant treatment of locally advanced gastric\/gastroesophageal junction adenocarcinoma: study protocol for a prospective, multicenter, single-arm phase IB\/II clinical trial.\u00a0Front Immunol. 2024;15:1431957. https:\/\/doi.org\/10.3389\/Fimmu.2024.1431957.","journal-title":"Front Immunol."},{"issue":"4","key":"20114_CR25","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1038\/S41568-020-0246-1","volume":"20","author":"M Mclaughlin","year":"2020","unstructured":"Mclaughlin M, Patin EC, Pedersen M, et al. Inflammatory microenvironment remodelling by tumour cells after radiotherapy. Nat Rev Cancer. 2020;20(4):203\u201317. https:\/\/doi.org\/10.1038\/S41568-020-0246-1.","journal-title":"Nat Rev Cancer."},{"key":"20114_CR26","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/J.Canlet.2020.12.045","volume":"502","author":"NE Donlon","year":"2021","unstructured":"Donlon NE, Power R, Hayes C, Reynolds JV, Lysaght J. Radiotherapy, immunotherapy, and the tumour microenvironment: turning an immunosuppressive milieu into a therapeutic opportunity. Cancer Lett. 2021;502:84\u201396. https:\/\/doi.org\/10.1016\/J.Canlet.2020.12.045.","journal-title":"Cancer Lett."},{"key":"20114_CR27","doi-asserted-by":"publisher","DOI":"10.1001\/Jamasurg.2026.0861","author":"J Okui","year":"2026","unstructured":"Okui J, Prakash LR, Lyu HG, et al. Immunotherapy response in microsatellite instability-high gastroesophageal adenocarcinoma. Jama Surg. 2026. https:\/\/doi.org\/10.1001\/Jamasurg.2026.0861.","journal-title":"Jama Surg."},{"issue":"5","key":"20114_CR28","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1001\/Jama.2025.20034","volume":"335","author":"AK Patel","year":"2026","unstructured":"Patel AK, Sethi NS, Park H. Gastric cancer: a review. Jama. 2026;335(5):439\u201350. https:\/\/doi.org\/10.1001\/Jama.2025.20034.","journal-title":"Jama."},{"issue":"9","key":"20114_CR29","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1001\/Jamaoncol.2016.6762","volume":"3","author":"EC Smyth","year":"2017","unstructured":"Smyth EC, Wotherspoon A, Peckitt C, et al. Mismatch repair deficiency, microsatellite instability, and survival: an exploratory analysis of the medical research council adjuvant gastric infusional chemotherapy (magic) trial. Jama Oncol. 2017;3(9):1197\u2013203. https:\/\/doi.org\/10.1001\/Jamaoncol.2016.6762.","journal-title":"Jama Oncol."},{"issue":"2","key":"20114_CR30","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1200\/Jco.22.00686","volume":"41","author":"T Andr\u00e9","year":"2023","unstructured":"Andr\u00e9 T, Tougeron D, Piessen G, et al. Neoadjuvant nivolumab plus ipilimumab and adjuvant nivolumab in localized deficient mismatch repair\/microsatellite instability-high gastric or esophagogastric junction adenocarcinoma: the gercor neonipiga phase Ii study. J Clin Oncol. 2023;41(2):255\u201365. https:\/\/doi.org\/10.1200\/Jco.22.00686.","journal-title":"J Clin Oncol."},{"issue":"3","key":"20114_CR31","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/J.Annonc.2024.11.016","volume":"36","author":"A Raimondi","year":"2025","unstructured":"Raimondi A, Lonardi S, Murgioni S, et al. Tremelimumab and durvalumab as neoadjuvant or non-operative management strategy of patients with microsatellite instability-high resectable gastric or gastroesophageal junction adenocarcinoma: the infinity study by gono. Ann Oncol. 2025;36(3):285\u201396. https:\/\/doi.org\/10.1016\/J.Annonc.2024.11.016.","journal-title":"Ann Oncol."},{"issue":"9742","key":"20114_CR32","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1016\/S0140-6736(10)61121-X","volume":"376","author":"Y-J Bang","year":"2010","unstructured":"Bang Y-J, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of Her2-positive advanced gastric or gastro-oesophageal junction cancer (TOGA): a phase 3, open-label, randomised controlled trial. The Lancet. 2010;376(9742):687\u201397. https:\/\/doi.org\/10.1016\/S0140-6736(10)61121-X.","journal-title":"The Lancet."},{"issue":"6","key":"20114_CR33","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.1002\/Ijc.33696","volume":"149","author":"R-D Hofheinz","year":"2021","unstructured":"Hofheinz R-D, Hegewisch-Becker S, Kunzmann V, et al. Trastuzumab in combination with 5-fluorouracil, leucovorin, oxaliplatin and docetaxel as perioperative treatment for patients with human epidermal growth factor receptor 2-positive locally advanced esophagogastric adenocarcinoma: a phase Ii trial of the arbeitsgemeinschaft Internistische onkologie gastric cancer study group. Int J Cancer. 2021;149(6):1322\u201331. https:\/\/doi.org\/10.1002\/Ijc.33696.","journal-title":"Int J Cancer."},{"issue":"32","key":"20114_CR34","doi-asserted-by":"publisher","first-page":"3750","DOI":"10.1200\/Jco.22.00380","volume":"40","author":"RD Hofheinz","year":"2022","unstructured":"Hofheinz RD, Merx K, Haag GM, et al. Flot versus flot\/trastuzumab\/pertuzumab perioperative therapy of human epidermal growth factor receptor 2\u2013positive resectable esophagogastric adenocarcinoma: a randomized phase Ii trial of the Aio Ega study group. J Clin Oncol. 2022;40(32):3750\u201361. https:\/\/doi.org\/10.1200\/Jco.22.00380.","journal-title":"J Clin Oncol."},{"issue":"2","key":"20114_CR35","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/S1470-2045(21)00718-X","volume":"23","author":"HP Safran","year":"2022","unstructured":"Safran HP, Winter K, Ilson DH, et al. Trastuzumab with trimodality treatment for oesophageal adenocarcinoma with her2 overexpression (Nrg oncology\/Rtog 1010): a multicentre, randomised, phase 3 trial. Lancet Oncol. 2022;23(2):259\u201369. https:\/\/doi.org\/10.1016\/S1470-2045(21)00718-X.","journal-title":"Lancet Oncol."},{"issue":"12","key":"20114_CR36","doi-asserted-by":"publisher","first-page":"4197","DOI":"10.1038\/S41591-025-03979-Y","volume":"31","author":"A Stein","year":"2025","unstructured":"Stein A, Goekkurt E, Al-Batran S-E, et al. Perioperative pembrolizumab, trastuzumab and flot in her2-positive localized esophagogastric adenocarcinoma: a phase 2 trial. Nat Med. 2025;31(12):4197\u2013204. https:\/\/doi.org\/10.1038\/S41591-025-03979-Y.","journal-title":"Nat Med."},{"issue":"5","key":"20114_CR37","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1200\/Jco.23.01208","volume":"42","author":"FS Verheij","year":"2024","unstructured":"Verheij FS, Omer DM, Williams H, et al. Long-term results of organ preservation in patients with rectal adenocarcinoma treated with total neoadjuvant therapy: the randomized phase Ii opra trial. J Clin Oncol. 2024;42(5):500\u20136. https:\/\/doi.org\/10.1200\/Jco.23.01208.","journal-title":"J Clin Oncol."},{"issue":"23","key":"20114_CR38","doi-asserted-by":"publisher","first-page":"2546","DOI":"10.1200\/Jco.22.00032","volume":"40","author":"J Garcia-Aguilar","year":"2022","unstructured":"Garcia-Aguilar J, Patil S, Gollub MJ, et al. Organ preservation in patients with rectal adenocarcinoma treated with total neoadjuvant therapy. J Clin Oncol. 2022;40(23):2546\u201356. https:\/\/doi.org\/10.1200\/Jco.22.00032.","journal-title":"J Clin Oncol."},{"key":"20114_CR39","doi-asserted-by":"publisher","unstructured":"Goetze T, Angermeier S, Debus J, et al. Organ preservation with durvalumab-based immunotherapy in combination with chemoradiation as definitive therapy for early stage, Ct1, and Ct2n0 esophageal adenocarcinoma with indication for radical surgery: a prospective, multicenter study of the Flot-Aio gastric cancer group (Ikf-T057\/Presto Trial). J Clin Oncol. 2024;42(3_Suppl):Tps431-Tps431. https:\/\/doi.org\/10.1200\/Jco.2024.42.3_Suppl.Tps431","DOI":"10.1200\/Jco.2024.42.3_Suppl.Tps431"}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-026-20114-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-026-20114-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-026-20114-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T17:51:53Z","timestamp":1789667513000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-026-20114-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,7]]},"references-count":39,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["20114"],"URL":"https:\/\/doi.org\/10.1245\/s10434-026-20114-4","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,7]]},"assertion":[{"value":"1 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Yanghee Woo - SAB for AstraZeneca.","order":1,"name":"Ethics","label":"Disclosure","group":{"name":"EthicsHeading","label":"Ethics"}}]}}